In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Gene therapy – affordability, access and reimbursement
Brian Huber, Vice President, Drug Development Services, considers the affordability, access and reimbursement challenges within the gene therapy market.
-
How CRO venture capital relationships can help biotech fundraising
This article considers how partnering with a CRO can help emerging biotechs to secure funding.
-
JPM 2022: Decentralised trials, broader service offerings and novel drugs key trends in the CRO space
In this snapshot from the J.P. Morgan Healthcare Conference, Steve Cutler comments on ICON’s success in decentralised trials and therapeutic technologies such as mRNA and checkpoint inhibitors.
-
ICON issues financial guidance for 2022 as the CRO giant eyes spike in revenue growth
This article discusses ICON’s forecast revenues for 2022 and includes a statement from Steve Cutler on ICON’s successes from 2021.
-
The personalised medicine paradigm
Cindy Spittle shares insights on the growth of molecular diagnostic testing in clinical trials.
-
Estimands: bringing clarity and focus to research questions in clinical trials
ICON's biostatistics experts offer their insights on the role of estimands in clinical research.
-
Sharing clinical trial results with paediatric participants
Kirsten Sherman Cervati contributes to this media article which discusses the considerations for returning results to paediatric participants.
-
Resisting change: The pathway to better AMR planning
Caroline Forkin, Vice President for Clinical Research Services, offers her insights on the various actions that should be taken to improve AMR planning.
This article was taken from Pharmafile Autumn 2021, page 12. Samedan Ltd.
-
In-Home Services: A patient-centric approach to improving recruitment and retention in clinical trials
Advances in wearables, telemedicine and remote monitoring technology along with the convenience of in-home visits were bound to make decentralised and hybrid clinical trials standard with enough time. However, the COVID-19 pandemic accelerated their adoption and now, even with the hope that the pandemic will soon be behind us, hybrid and decentralised models are poised to become viable solutions in clinical trial design because of their inherent agility, inclusivity and most importantly, patient centricity.
-
